Inside US Aging Research: The Institutes, Trials and Funding Shaping Longevity Science in 2026
20 September 2026 · 8 min read
The United States is the centre of gravity for ageing research, home to the world's largest public funder of the field, its most-watched clinical trials and an expanding base of private capital. This article maps the landscape for researchers, clinicians, investors and curious readers who want to understand where the science is heading.
The public engine, the National Institute on Aging
The National Institute on Aging, part of the National Institutes of Health, is the primary federal funder of ageing research in the US. Its programmes span basic biology, translational geroscience, Alzheimer's disease and related dementias, and clinical trials. Its Interventions Testing Program has spent two decades rigorously testing compounds in mice, producing some of the field's most cited results, including early evidence for rapamycin.
Public funding matters because it de-risks the questions private capital will not touch, long timescales, unpatentable compounds, and the basic biology on which everything else depends.
Trials that could change the field
The TAME trial, Targeting Aging with Metformin, is the field's reference point. Led by researchers at the Albert Einstein College of Medicine and coordinated by the American Federation for Aging Research, it tests whether metformin delays the onset of multiple age-related diseases in older adults. Whatever its outcome, TAME is designed to show regulators a pathway for approving therapies that target ageing biology rather than single diseases.
Alongside it, a growing portfolio of trials tests senolytics, NAD-related compounds, GLP-1 medicines and exercise mimetics against ageing-related endpoints. Results have been mixed, which is normal for a young field, and the failures are as instructive as the successes.
The private and philanthropic surge
Private investment in longevity biotechnology has grown from a niche to a multi-billion-dollar category over the past decade. Philanthropic funders have changed the scale of ambition: the Hevolution Foundation has committed up to one billion dollars to healthspan science, and the XPRIZE Healthspan competition offers one hundred and one million dollars for therapies that restore function in older adults.
This capital brings speed and talent, but also pressure to overstate results. The healthiest parts of the US landscape pair investment with scientific governance, peer review and honest communication about uncertainty.
What it means for healthy longevity
The direction of travel is clear. Ageing biology is moving from the periphery of medicine towards its centre, and the US leads that shift in funding, trials and talent. The open questions are translational: which interventions work in humans, how to measure their effects credibly, and how to deliver benefits equitably.
Those are precisely the questions MR Longevity exists to help answer, by connecting science, clinical validation, responsible innovation and public understanding across borders. If you work in this space, we invite you to collaborate with the mission.
- National Institute on Aging
- TAME Trial, American Federation for Aging Research
- Hevolution Foundation
- XPRIZE Healthspan
This article is for general information only and is not medical advice. Decisions about your health should be made with a qualified clinician.